Haemonetics Corporation
HAENYSEHealthcare● Active
$72.23
+$0.95(+1.33%)
Market Cap$3.3B
P/E Ratio—
52W High$87.32
52W Low$47.32
Haemonetics Corporation (HAE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HAE · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$1.29
Est. $1.28 · +0.8%
Revenue
$0.35B
Est. $0.34B · +2.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat Revenue🔥 7-Quarter EPS Beat Streak
HAE reports quarterly as a NYSE-listed Medical - Instruments & Supplies company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.36
Rev. $5.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.36
Rev. Est.$5.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $1.09 | — | — | — | $0.33B | — |
| — Q2 FY2026 | May 7, 2026 | $1.28 | $1.29 | +0.8% | $0.35B | $0.34B | +2.8% |
| ▲ Q1 FY2026 | Feb 5, 2026 | $1.27 | $1.31 | +3.1% | $0.34B | $0.33B | +2.1% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $1.12 | $1.27 | +13.4% | $0.33B | $0.33B | -0.8% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $1.01 | $1.10 | +8.9% | $0.32B | $0.32B | +0.4% |
| ▲ Q2 FY2025 | May 8, 2025 | $1.22 | $1.24 | +1.6% | $0.33B | $0.31B | +5.8% |
| — Q1 FY2025 | Feb 6, 2025 | $1.18 | $1.19 | +0.8% | $0.35B | $0.35B | -1.7% |
| ▲ Q4 FY2024 | Nov 7, 2024 | $1.09 | $1.12 | +2.8% | $0.35B | $0.34B | +0.8% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$1.09
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026
EPS Actual
$1.29
EPS Est.
$1.28
EPS Surpr.
+0.8%
Revenue
$0.35B
Q1 FY2026
Feb 5, 2026Beat
EPS Actual
$1.31
EPS Est.
$1.27
EPS Surpr.
+3.1%
Revenue
$0.34B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$1.27
EPS Est.
$1.12
EPS Surpr.
+13.4%
Revenue
$0.33B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$1.10
EPS Est.
$1.01
EPS Surpr.
+8.9%
Revenue
$0.32B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$1.24
EPS Est.
$1.22
EPS Surpr.
+1.6%
Revenue
$0.33B
Q1 FY2025
Feb 6, 2025
EPS Actual
$1.19
EPS Est.
$1.18
EPS Surpr.
+0.8%
Revenue
$0.35B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$1.12
EPS Est.
$1.09
EPS Surpr.
+2.8%
Revenue
$0.35B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $1.46 | $1.50 | $1.55 | 4 |
| Q4 FY2027 | $1.47 | $1.51 | $1.56 | 3 |
| Q3 FY2027 | $1.40 | $1.44 | $1.49 | 3 |
| Q2 FY2027 | $1.21 | $1.25 | $1.29 | 3 |
| Q1 FY2027 | $1.42 | $1.46 | $1.51 | 3 |
| Q4 FY2026 | $1.34 | $1.38 | $1.42 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $0.4B | $0.4B | $0.4B | 3 |
| Q4 FY2027 | $0.4B | $0.4B | $0.4B | 4 |
| Q3 FY2027 | $0.4B | $0.4B | $0.4B | 4 |
| Q2 FY2027 | $0.3B | $0.4B | $0.4B | 4 |
| Q1 FY2027 | $0.4B | $0.4B | $0.4B | 4 |
| Q4 FY2026 | $0.3B | $0.4B | $0.4B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +0.8% | $52.67 | $54.37 | +3.23% |
| ▲ Q1 FY2026 | Feb 5, 2026 | +3.1% | $65.95 | $65.02 | -1.41% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +13.4% | $50.72 | $67.11 | +32.31% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +8.9% | $75.77 | $55.63 | -26.58% |
| ▲ Q2 FY2025 | May 8, 2025 | +1.6% | $64.25 | $68.01 | +5.85% |
| ▲ Q1 FY2025 | Feb 6, 2025 | +0.8% | $71.24 | $62.99 | -11.58% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +2.8% | $78.16 | $86.53 | +10.71% |
| ▲ Q3 FY2024 | Aug 8, 2024 | -1.0% | $85.72 | $76.43 | -10.84% |
Q2 FY2026+3.23%
Report Date
May 7, 2026
EPS Beat/Miss
+0.8%
Price Before
$52.67
Price After
$54.37
Q1 FY2026-1.41%
Report Date
Feb 5, 2026
EPS Beat/Miss
+3.1%
Price Before
$65.95
Price After
$65.02
Q4 FY2025+32.31%
Report Date
Nov 6, 2025
EPS Beat/Miss
+13.4%
Price Before
$50.72
Price After
$67.11
Q3 FY2025-26.58%
Report Date
Aug 7, 2025
EPS Beat/Miss
+8.9%
Price Before
$75.77
Price After
$55.63
Q2 FY2025+5.85%
Report Date
May 8, 2025
EPS Beat/Miss
+1.6%
Price Before
$64.25
Price After
$68.01
Q1 FY2025-11.58%
Report Date
Feb 6, 2025
EPS Beat/Miss
+0.8%
Price Before
$71.24
Price After
$62.99
Q4 FY2024+10.71%
Report Date
Nov 7, 2024
EPS Beat/Miss
+2.8%
Price Before
$78.16
Price After
$86.53
Q3 FY2024-10.84%
Report Date
Aug 8, 2024
EPS Beat/Miss
-1.0%
Price Before
$85.72
Price After
$76.43
Avg Beat Reaction+0.21%
Beat Rate8 / 8 quarters
Largest Move+32.31% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HAE ends December
Haemonetics Corporation (HAE) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $1.29 (in line with the analyst consensus of $1.28). HAE has beaten EPS estimates for 7 consecutive quarters. The next HAE earnings date is expected around September 1, 2026.
Each quarter, investors track HAE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HAE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HAE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HAE earnings · 4 questionsHaemonetics Corporation's next earnings report is expected around September 1, 2026. HAE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HAE historically reports after market close (AMC).
HAE earnings datewhen is HAE earningsHAE next earnings datewhen does HAE report earningsHAE earnings calendar
▸ Source: FMP · Haemonetics Corporation SEC filings · US GAAP · Haemonetics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026